Safety Reading Notes

Read safety context beside the research guide.

The Minor cannabinoids safety review source set includes safety-context rows around safety, adverse-event, impairment, or formulation-specific concerns: insufficient. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 41142233

Evidence class: insufficient

PubMed For Dummies Article

Minor cannabinoids safety review Evidence Review: the long-form source walk-through

Quick read
  • Minor cannabinoids safety review currently has 36 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 41142233
  • The evidence classes most visible in the row language are insufficient (21), preliminary human (8), mechanistic or pharmacological (4), and preclinical (3). PMID 21845389
  • The study-design language most visible in the row language is Narrative or expert review (7), Human clinical study (7), Case report or case series (3), and other mapped categories (11). PMID 41548880
  • The repeated topics are safety, adverse-event, impairment, or formulation-specific concerns (36), which tells the reader where to start opening PubMed and DOI links. PMID 40708053

Start with the research question

Minor cannabinoids safety review is built from 36 source-backed evidence row(s) and 36 research source(s). The current evidence classes read as insufficient (21), preliminary human (8), mechanistic or pharmacological (4), and preclinical (3), and the study-design language most often reads as Narrative or expert review (7), Human clinical study (7), Case report or case series (3), and other mapped categories (11). PMID 41142233

The row-level question is not simply whether Minor cannabinoids safety review is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are safety, adverse-event, impairment, or formulation-specific concerns (36). PMID 42158949

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 42158949

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 41698831

Mechanistic evidence 0 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 37217977

Limits and uncertainty 57 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 38868665

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 39805119

Where this page has the most source density

The largest bucket surfaced for this page is safety, adverse-event, impairment, or formulation-specific concerns: insufficient. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is safety, adverse-event, impairment, or formulation-specific concerns: preliminary human, which gives readers another way to see what the literature repeatedly circles. PMID 41142233

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 42158949

Bucket chapters: what the literature is circling

safety, adverse-event, impairment, or formulation-specific concerns: insufficient

21 research sources 21 rows (93-200) Evidence class: insufficient

This bucket summarizes source-backed rows focused on safety, adverse-event, impairment, or formulation-specific concerns: insufficient. It currently draws from 21 research source(s), so the exact study type matters. PMID 41142233

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 41142233

  • Evidence row 93

    Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review... PMID 41142233

  • Evidence row 200

    CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse... PMID 37593907

safety, adverse-event, impairment, or formulation-specific concerns: preliminary human

8 research sources 8 rows (97-169) Evidence class: preliminary human

This bucket summarizes source-backed rows focused on safety, adverse-event, impairment, or formulation-specific concerns: preliminary human. It currently draws from 8 research source(s), so the exact study type matters. PMID 42158949

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 42158949

  • Evidence row 97

    Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, adverse-ev... PMID 42158949

  • Evidence row 169

    CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome... PMID 37162192

safety, adverse-event, impairment, or formulation-specific concerns: mechanistic or pharmacological

4 research sources 4 rows (157, 161, 164, 165) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on safety, adverse-event, impairment, or formulation-specific concerns: mechanistic or pharmacological. It currently draws from 4 research source(s), so the exact study type matters. PMID 39596290

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 39596290

  • Evidence row 157

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro... PMID 39596290

  • Evidence row 161

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vi... PMID 42163693

safety, adverse-event, impairment, or formulation-specific concerns: preclinical

3 research sources 3 rows (171, 172, 174) Evidence class: preclinical

This bucket summarizes source-backed rows focused on safety, adverse-event, impairment, or formulation-specific concerns: preclinical. It currently draws from 3 research source(s), so the exact study type matters. PMID 40580638

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 40580638

  • Evidence row 171

    CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event,... PMID 40580638

  • Evidence row 172

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse... PMID 37721989

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (0 row(s)), and safety/tolerability context (36 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 41142233

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 42158949

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 38176407
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 36742440
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 36941718

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 41142233

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 42158949

Source-reading checklist for Minor cannabinoids safety review

  1. Open the linked PubMed or DOI record. PMID 38696245
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 39596290
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 11152013
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 37947792
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 40206058

Source Notes

Minor cannabinoids safety review source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 93

    Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 41142233

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacologic treatment of fibromyalgia: an update.
  2. Evidence row 94

    Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 21845389

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.
  3. Evidence row 95

    Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Meta-analysis or systematic evidence synthesis; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 41548880

    Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Cannabis-based medicines for chronic neuropathic pain in adults.
  4. Evidence row 96

    Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 40708053

    Evidence class: insufficient. Source: Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.
  5. Evidence row 97

    Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 42158949

    Evidence class: preliminary human. Source: Adverse events associated with medical cannabis reported within a centralized call center.
  6. Evidence row 149

    CBN studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 41698831

    Evidence class: preliminary human; Study design: Human clinical study. Source: Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
  7. Evidence row 150

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37217977

    Evidence class: insufficient; Study design: Case report or case series. Source: Self-reported adverse events associated with ∆8-Tetrahydrocannabinol (Delta-8-THC) Use.
  8. Evidence row 151

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 38868665

    Evidence class: insufficient; Study design: Systematic review. Source: Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis.
  9. Evidence row 152

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 39805119

    Evidence class: insufficient; Study design: Systematic review. Source: Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review.
  10. Evidence row 153

    Cannabinoids studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 38176407

    Evidence class: insufficient. Source: Prevalence of carboxy-Δ8-tetrahydrocannabiniol in antidoping samples.
  11. Evidence row 154

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 36742440

    Evidence class: insufficient; Study design: Case report or case series. Source: Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
  12. Evidence row 155

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Case report or case series; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 36941718

    Evidence class: preliminary human; Study design: Case report or case series. Source: Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report.
  13. Evidence row 156

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 38696245

    Evidence class: preliminary human. Source: Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection.
  14. Evidence row 157

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 39596290

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.
  15. Evidence row 158

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 11152013

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in clinical practice.
  16. Evidence row 159

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37947792

    Evidence class: preliminary human; Study design: Human clinical study. Source: A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS).
  17. Evidence row 160

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 40206058

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system.
  18. Evidence row 161

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 42163693

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine.
  19. Evidence row 162

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 38496308

    Evidence class: preliminary human; Study design: Human clinical study. Source: Safety study of cannabidiol products in healthy dogs.
  20. Evidence row 163

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 42057192

    Evidence class: preliminary human. Source: Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract.
  21. Evidence row 164

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 39004335

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids.
  22. Evidence row 165

    CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 41822224

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs.
  23. Evidence row 166

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 38777605

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Potential of Cannabichromene (CBC) as a Therapeutic Agent.
  24. Evidence row 167

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  25. Evidence row 168

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37630401

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review.
  26. Evidence row 169

    CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preliminary human (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37162192

    Evidence class: preliminary human; Study design: Human clinical study. Source: The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial.
  27. Evidence row 170

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (study design: Systematic review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 38229238

    Evidence class: insufficient; Study design: Systematic review. Source: A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics.
  28. Evidence row 171

    CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 40580638

    Evidence class: preclinical; Study design: Animal study. Source: Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.
  29. Evidence row 172

    Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37721989

    Evidence class: preclinical; Study design: Animal study. Source: Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.
  30. Evidence row 173

    CBC studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 33903673

    Evidence class: insufficient. Source: CBD, a precursor of THC in e-cigarettes.
  31. Evidence row 174

    CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 36916438

    Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
  32. Evidence row 196

    CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 30374683

    Evidence class: insufficient; Study design: Human clinical study. Source: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
  33. Evidence row 197

    CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 39585547

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Update on Cannabidiol in Drug-Resistant Epilepsy.
  34. Evidence row 198

    CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 31802404

    Evidence class: insufficient; Study design: Human clinical study. Source: A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
  35. Evidence row 199

    CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 33667843

    Evidence class: insufficient. Source: Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
  36. Evidence row 200

    CBD studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 37593907

    Evidence class: insufficient. Source: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program.